

## ANTICONVULSANT STEP THERAPY

---

### Products Affected

#### Step 2:

- APTIOM 200 MG TABLET
- APTIOM 400 MG TABLET
- APTIOM 600 MG TABLET
- APTIOM 800 MG TABLET
- BRIVIACT 10 MG TABLET
- BRIVIACT 10 MG/ML ORAL SOLUTION
- BRIVIACT 100 MG TABLET
- BRIVIACT 25 MG TABLET
- BRIVIACT 50 MG TABLET
- BRIVIACT 75 MG TABLET
- FYCOMPA 0.5 MG/ML ORAL SUSPENSION
- FYCOMPA 10 MG TABLET
- FYCOMPA 12 MG TABLET
- FYCOMPA 2 MG TABLET
- FYCOMPA 4 MG TABLET
- FYCOMPA 6 MG TABLET
- FYCOMPA 8 MG TABLET
- SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 250 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 500 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 750 MG TABLET FOR ORAL SUSPENSION
- VIMPAT 10 MG/ML ORAL SOLUTION
- VIMPAT 100 MG TABLET
- VIMPAT 150 MG TABLET
- VIMPAT 200 MG TABLET
- VIMPAT 50 MG TABLET

### Details

Criteria
Step 1: First line therapy should be a documented trial of two of the following formulary medications: carbamazepine, carbamazepine ER, divalproex sodium, divalproex sodium ER, gabapentin, lamotrigine, lamotrigine ER, levetiracetam, levetiracetam ER, oxcarbazepine, valproic acid, zonisamide, phenytoin, phenytoin ER, felbamate, ethosuxamide, topiramate, primidone, Dilantin, phenobarbital, Phenytek or tiagabine. Step 2: Once two of the medications listed in Step 1 have been tried, patients can receive therapy with Aptiom, Spritam, Fycompa, Briviact or Vimpat.

# ANTIDEPRESSANT STEP THERAPY

---

## Products Affected

### Step 2:

- FETZIMA 120 MG  
CAPSULE,EXTENDED RELEASE
- FETZIMA 20 MG (2)-40 MG (26)  
CAPSULE,EXTENDED RELEASE,24  
HR,DOSE PACK
- FETZIMA 20 MG  
CAPSULE,EXTENDED RELEASE
- FETZIMA 40 MG  
CAPSULE,EXTENDED RELEASE
- FETZIMA 80 MG  
CAPSULE,EXTENDED RELEASE
- TRINTELLIX 10 MG TABLET
- TRINTELLIX 20 MG TABLET
- TRINTELLIX 5 MG TABLET
- VIIBRYD 10 MG (7)-20 MG (23)  
TABLETS IN A DOSE PACK
- VIIBRYD 10 MG TABLET
- VIIBRYD 20 MG TABLET
- VIIBRYD 40 MG TABLET

## Details

---

Criteria
Step 1: First line therapy should be a documented trial of two of the following formulary medications: citalopram, duloxetine, escitalopram, fluoxetine, paroxetine, sertraline, venlafaxine, venlafaxine ER or desvenlafaxine. Step 2: Once two of the medications listed in step 1 have been tried, patient can receive therapy with Trintellix, Fetzima or Viibryd.

2019 1 Tier Standard-SCHA  
Document: 2019 Step Therapy Criteria  
Formulary ID: 19426  
Last Updated: 11/2018  
Effective Date: 01/01/2019

## AZOPT STEP THERAPY

---

### Products Affected

#### Step 2:

- AZOPT 1 % EYE  
DROPS,SUSPENSION

### Details

---

Criteria
Step 1: First line therapy should be a documented trial of formulary dorzolamide or dorzolamide/timolol. Step 2: Once dorzolamide or dorzolamide/timolol has been tried, the patient can receive therapy with Azopt.

# COMBIVENT STEP THERAPY

---

## Products Affected

### Step 2:

- COMBIVENT RESPIMAT 20 MCG-100 MCG/ACTUATION SOLUTION FOR INHALATION

## Details

---

Criteria
Step 1: First line therapy should be a documented trial of formulary Anoro Ellipta. Step 2: Once Anoro Ellipta has been tried, patients can receive therapy with Combivent Respimat.

2019 1 Tier Standard-SCHA  
Document: 2019 Step Therapy Criteria  
Formulary ID: 19426  
Last Updated: 11/2018  
Effective Date: 01/01/2019

## GLP-1 AGONIST STEP THERAPY

---

### Products Affected

#### Step 2:

- TRULICITY 0.75 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR
- TRULICITY 1.5 MG/0.5 ML SUBCUTANEOUS PEN INJECTOR
- VICTOZA 3-PAK 0.6 MG/0.1 ML (18 MG/3 ML) SUBCUTANEOUS PEN INJECTOR

### Details

<b>Criteria</b>	Step 1: First line therapy should be a documented trial of a formulary metformin tablet or metformin ER tablet. Step 2: Once metformin tablet or metformin ER tablet has been tried, patients can receive therapy with Victoza or Trulicity.
-----------------	--

# HYPOGLYCEMICS STEP THERAPY

---

## Products Affected

### Step 2:

- *acarbose 100 mg tablet*
- *acarbose 25 mg tablet*
- *acarbose 50 mg tablet*
- *alogliptin 12.5 mg tablet*
- *alogliptin 12.5 mg-metformin 1,000 mg tablet*
- *alogliptin 12.5 mg-metformin 500 mg tablet*
- *alogliptin 12.5 mg-pioglitazone 15 mg tablet*
- *alogliptin 12.5 mg-pioglitazone 30 mg tablet*
- *alogliptin 12.5 mg-pioglitazone 45 mg tablet*
- *alogliptin 25 mg tablet*
- *alogliptin 25 mg-pioglitazone 15 mg tablet*
- *alogliptin 25 mg-pioglitazone 30 mg tablet*
- *alogliptin 25 mg-pioglitazone 45 mg tablet*
- *alogliptin 6.25 mg tablet*
- AVANDIA 2 MG TABLET
- AVANDIA 4 MG TABLET
- INVOKAMET 150 MG-1,000 MG TABLET
- INVOKAMET 150 MG-500 MG TABLET
- INVOKAMET 50 MG-1,000 MG TABLET
- INVOKAMET 50 MG-500 MG TABLET
- INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKANA 100 MG TABLET
- INVOKANA 300 MG TABLET
- JANUMET 50 MG-1,000 MG TABLET
- JANUMET 50 MG-500 MG TABLET
- JANUMET XR 100 MG-1,000 MG TABLET,EXTENDED RELEASE
- JANUMET XR 50 MG-1,000 MG TABLET,EXTENDED RELEASE
- JANUMET XR 50 MG-500 MG TABLET,EXTENDED RELEASE
- JANUVIA 100 MG TABLET
- JANUVIA 25 MG TABLET
- JANUVIA 50 MG TABLET
- JENTADUETO 2.5 MG-1,000 MG TABLET
- JENTADUETO 2.5 MG-500 MG TABLET
- JENTADUETO 2.5 MG-850 MG TABLET
- JENTADUETO XR 2.5 MG-1,000 MG TABLET, EXTENDED RELEASE
- JENTADUETO XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE
- *nateglinide 120 mg tablet*
- *nateglinide 60 mg tablet*
- *pioglitazone 15 mg tablet*
- *pioglitazone 15 mg-metformin 500 mg tablet*
- *pioglitazone 15 mg-metformin 850 mg tablet*
- *pioglitazone 30 mg tablet*
- *pioglitazone 45 mg tablet*
- *repaglinide 0.5 mg tablet*
- *repaglinide 1 mg tablet*
- *repaglinide 2 mg tablet*
- SEGLUROMET 2.5 MG-1,000 MG TABLET
- SEGLUROMET 2.5 MG-500 MG TABLET

2019 1 Tier Standard-SCHA  
Document: 2019 Step Therapy Criteria  
Formulary ID: 19426  
Last Updated: 11/2018  
Effective Date: 01/01/2019

- SEGLUROMET 7.5 MG-1,000 MG TABLET
- SEGLUROMET 7.5 MG-500 MG TABLET
- STEGLATRO 15 MG TABLET
- STEGLATRO 5 MG TABLET
- STEGLUJAN 15 MG-100 MG TABLET
- STEGLUJAN 5 MG-100 MG TABLET
- TRADJENTA 5 MG TABLET

## Details

<b>Criteria</b>	Step 1: First line therapy should be a documented trial with a formulary sulfonylurea, metformin or formulary insulin (if appropriate). Step 2: Once one of these agents has been tried, patients can receive therapy with other formulary hypoglycemics such as Avandia, acarbose, Januvia, Janumet, Janumet XR, repaglinide, nateglinide, pioglitazone, pioglitazone/metformin, alogliptin, alogliptin/metformin, alogliptin/pioglitazone, Tradjenta, Jentadueto, Jentadueto XR, Invokana, Invokamet, Invokamet XR, Steglatro, Segluromet or Steglujan
-----------------	--

# KRISTALOSE STEP THERAPY

---

## Products Affected

### Step 2:

- KRISTALOSE 10 GRAM ORAL PACKET
- KRISTALOSE 20 GRAM ORAL PACKET

## Details

---

Criteria
Step 1: First line therapy should be a documented trial of formulary Constulose, lactulose, or polyethylene glycol. Step 2: Once Constulose, lactulose, or polyethylene glycol has been tried, patients can receive therapy with Kristalose packet.



2019 1 Tier Standard-SCHA  
Document: 2019 Step Therapy Criteria  
Formulary ID: 19426  
Last Updated: 11/2018  
Effective Date: 01/01/2019

## RANEXA STEP THERAPY

---

### Products Affected

#### Step 2:

- RANEXA 1,000 MG  
TABLET,EXTENDED RELEASE
- RANEXA 500 MG  
TABLET,EXTENDED RELEASE

### Details

---

Criteria
Step 1: First line therapy should be a documented trial of a formulary beta blocker or a calcium channel blocker. Step 2: Once a beta blocker or a calcium channel blocker has been tried, patients may receive therapy with Ranolazine (Ranexa).

# TOPICAL IMMUNOMODULATORS STEP THERAPY

---

## Products Affected

### Step 2:

- ELIDEL 1 % TOPICAL CREAM
- *tacrolimus 0.1 % topical ointment*
- *tacrolimus 0.03 % topical ointment*

## Details

---

<b>Criteria</b>	Step 1: First line therapy should be a documented trial of two formulary topical corticosteroids. Step 2: Once two of these agents have been tried, patients can receive therapy with Elidel or generic topical tacrolimus.
-----------------	---

---

2019 1 Tier Standard-SCHA  
Document: 2019 Step Therapy Criteria  
Formulary ID: 19426  
Last Updated: 11/2018  
Effective Date: 01/01/2019

## TREXALL STEP THERAPY

---

### Products Affected

#### Step 2:

- TREXALL 10 MG TABLET
- TREXALL 15 MG TABLET
- TREXALL 5 MG TABLET
- TREXALL 7.5 MG TABLET

### Details

<b>Criteria</b>	Step 1: First line therapy should be a documented trial with formulary generic methotrexate. Step 2: Once generic methotrexate has been tried, patients can receive Trexall.
-----------------	--

# ULORIC STEP THERAPY

---

## Products Affected

### Step 2:

- ULORIC 40 MG TABLET
- ULORIC 80 MG TABLET

## Details

---

Criteria
Step 1: First line therapy should be a documented trial of formulary allopurinol tablet. Step 2: Once allopurinol tablet has been tried, patients can receive therapy with Uloric.

## URINARY INCONTINENCE AGENTS STEP THERAPY

---

### Products Affected

#### Step 2:

- *darifenacin er 15 mg tablet,extended release 24 hr*
- *darifenacin er 7.5 mg tablet,extended release 24 hr*

#### Step 3:

- MYRBETRIQ 25 MG TABLET,EXTENDED RELEASE
- MYRBETRIQ 50 MG TABLET,EXTENDED RELEASE

### Details

---

Criteria
Step 1: First line therapy should be a documented trial of formulary oxybutynin, oxybutynin ER, tolterodine or tolterodine ER. Step 2: Second line therapy should be formulary darifenacin ER. Step 3: Once oxybutynin, oxybutynin ER, tolterodine or tolterodine ER AND darifenacin ER have been tried, patients can receive therapy with Myrbetriq.

# ZAFIRLUKAST STEP THERAPY

---

## Products Affected

### Step 2:

- *zafirlukast 10 mg tablet*
- *zafirlukast 20 mg tablet*

## Details

---

<b>Criteria</b>	Step 1: First line therapy should be a documented trial of formulary montelukast. Step 2: Once montelukast has been tried, patients may receive therapy with zafirlukast.
-----------------	---

---

2019 1 Tier Standard-SCHA  
Document: 2019 Step Therapy Criteria  
Formulary ID: 19426  
Last Updated: 11/2018  
Effective Date: 01/01/2019

## ZIRGAN STEP THERAPY

---

### Products Affected

#### Step 2:

- ZIRGAN 0.15 % EYE GEL

### Details

---

<b>Criteria</b>	Step 1: First line therapy should be a documented trial of formulary generic trifluridine ophthalmic. Step 2: Once generic trifluridine ophthalmic has been tried, patients can receive therapy with Zirgan.
-----------------	--

---

## Index

### A

acarbose 100 mg tablet.....	6
acarbose 25 mg tablet.....	6
acarbose 50 mg tablet.....	6
alogliptin 12.5 mg tablet .....	6
alogliptin 12.5 mg-metformin 1,000 mg tablet.....	6
alogliptin 12.5 mg-metformin 500 mg tablet .....	6
alogliptin 12.5 mg-pioglitazone 15 mg tablet .....	6
alogliptin 12.5 mg-pioglitazone 30 mg tablet .....	6
alogliptin 12.5 mg-pioglitazone 45 mg tablet .....	6
alogliptin 25 mg tablet .....	6
alogliptin 25 mg-pioglitazone 15 mg tablet	6
alogliptin 25 mg-pioglitazone 30 mg tablet	6
alogliptin 25 mg-pioglitazone 45 mg tablet	6
alogliptin 6.25 mg tablet .....	6
APTIOM 200 MG TABLET .....	1
APTIOM 400 MG TABLET .....	1
APTIOM 600 MG TABLET .....	1
APTIOM 800 MG TABLET .....	1
AVANDIA 2 MG TABLET .....	6
AVANDIA 4 MG TABLET .....	6
AZOPT 1 % EYE DROPS,SUSPENSION	3
<b>B</b>	
BRIVIACT 10 MG TABLET.....	1
BRIVIACT 10 MG/ML ORAL SOLUTION .....	1
BRIVIACT 100 MG TABLET.....	1
BRIVIACT 25 MG TABLET.....	1
BRIVIACT 50 MG TABLET.....	1
BRIVIACT 75 MG TABLET.....	1
<b>C</b>	
COMBIVENT RESPIMAT 20 MCG-100 MCG/ACTUATION SOLUTION FOR INHALATION.....	4
<b>D</b>	
darifenacin er 15 mg tablet,extended release 24 hr .....	13
darifenacin er 7.5 mg tablet,extended release 24 hr .....	13

### E

ELIDEL 1 % TOPICAL CREAM .....	10
--------------------------------	----

### F

FETZIMA 120 MG CAPSULE,EXTENDED RELEASE .....	2
FETZIMA 20 MG (2)-40 MG (26) CAPSULE,EXTENDED RELEASE,24 HR,DOSE PACK .....	2
FETZIMA 20 MG CAPSULE,EXTENDED RELEASE .....	2
FETZIMA 40 MG CAPSULE,EXTENDED RELEASE .....	2
FETZIMA 80 MG CAPSULE,EXTENDED RELEASE .....	2
FYCOMPA 0.5 MG/ML ORAL SUSPENSION .....	1
FYCOMPA 10 MG TABLET .....	1
FYCOMPA 12 MG TABLET .....	1
FYCOMPA 2 MG TABLET .....	1
FYCOMPA 4 MG TABLET .....	1
FYCOMPA 6 MG TABLET .....	1
FYCOMPA 8 MG TABLET .....	1

### I

INVOKAMET 150 MG-1,000 MG TABLET .....	6
INVOKAMET 150 MG-500 MG TABLET	6
INVOKAMET 50 MG-1,000 MG TABLET .....	6
INVOKAMET 50 MG-500 MG TABLET.	6
INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE .....	6
INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE .....	6
INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE .....	6
INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE .....	6
INVOKANA 100 MG TABLET .....	6
INVOKANA 300 MG TABLET .....	6

### J

JANUMET 50 MG-1,000 MG TABLET ...	6
JANUMET 50 MG-500 MG TABLET .....	6
JANUMET XR 100 MG-1,000 MG TABLET,EXTENDED RELEASE .....	6



JANUMET XR 50 MG-1,000 MG  
 TABLET,EXTENDED RELEASE ..... 6  
 JANUMET XR 50 MG-500 MG  
 TABLET,EXTENDED RELEASE ..... 6  
 JANUVIA 100 MG TABLET ..... 6  
 JANUVIA 25 MG TABLET ..... 6  
 JANUVIA 50 MG TABLET ..... 6  
 JENTADUETO 2.5 MG-1,000 MG  
 TABLET ..... 6  
 JENTADUETO 2.5 MG-500 MG TABLET  
 ..... 6  
 JENTADUETO 2.5 MG-850 MG TABLET  
 ..... 6  
 JENTADUETO XR 2.5 MG-1,000 MG  
 TABLET, EXTENDED RELEASE ..... 6  
 JENTADUETO XR 5 MG-1,000 MG  
 TABLET, EXTENDED RELEASE ..... 6  
**K**  
 KRISTALOSE 10 GRAM ORAL PACKET  
 ..... 8  
 KRISTALOSE 20 GRAM ORAL PACKET  
 ..... 8  
**M**  
 MYRBETRIQ 25 MG  
 TABLET,EXTENDED RELEASE ..... 13  
 MYRBETRIQ 50 MG  
 TABLET,EXTENDED RELEASE ..... 13  
**N**  
 nateglinide 120 mg tablet..... 6  
 nateglinide 60 mg tablet..... 6  
**P**  
 pioglitazone 15 mg tablet..... 6  
 pioglitazone 15 mg-metformin 500 mg  
 tablet..... 6  
 pioglitazone 15 mg-metformin 850 mg  
 tablet..... 6  
 pioglitazone 30 mg tablet..... 6  
 pioglitazone 45 mg tablet..... 6  
**R**  
 RANEXA 1,000 MG  
 TABLET,EXTENDED RELEASE ..... 9  
 RANEXA 500 MG TABLET,EXTENDED  
 RELEASE..... 9

repaglinide 0.5 mg tablet..... 6  
 repaglinide 1 mg tablet..... 6  
 repaglinide 2 mg tablet..... 6  
**S**  
 SEGLUROMET 2.5 MG-1,000 MG  
 TABLET ..... 6  
 SEGLUROMET 2.5 MG-500 MG TABLET  
 ..... 6  
 SEGLUROMET 7.5 MG-1,000 MG  
 TABLET ..... 7  
 SEGLUROMET 7.5 MG-500 MG TABLET  
 ..... 7  
 SPRITAM 1,000 MG TABLET FOR ORAL  
 SUSPENSION ..... 1  
 SPRITAM 250 MG TABLET FOR ORAL  
 SUSPENSION ..... 1  
 SPRITAM 500 MG TABLET FOR ORAL  
 SUSPENSION ..... 1  
 SPRITAM 750 MG TABLET FOR ORAL  
 SUSPENSION ..... 1  
 STEGLATRO 15 MG TABLET ..... 7  
 STEGLATRO 5 MG TABLET ..... 7  
 STEGLUJAN 15 MG-100 MG TABLET .. 7  
 STEGLUJAN 5 MG-100 MG TABLET ... 7  
**T**  
 tacrolimus 0.03 % topical ointment ..... 10  
 tacrolimus 0.1 % topical ointment ..... 10  
 TRADJENTA 5 MG TABLET..... 7  
 TREXALL 10 MG TABLET..... 11  
 TREXALL 15 MG TABLET..... 11  
 TREXALL 5 MG TABLET..... 11  
 TREXALL 7.5 MG TABLET..... 11  
 TRINTELLIX 10 MG TABLET ..... 2  
 TRINTELLIX 20 MG TABLET ..... 2  
 TRINTELLIX 5 MG TABLET ..... 2  
 TRULICITY 0.75 MG/0.5 ML  
 SUBCUTANEOUS PEN INJECTOR .... 5  
 TRULICITY 1.5 MG/0.5 ML  
 SUBCUTANEOUS PEN INJECTOR .... 5  
**U**  
 ULORIC 40 MG TABLET..... 12  
 ULORIC 80 MG TABLET..... 12

**V**

VICTOZA 3-PAK 0.6 MG/0.1 ML (18  
MG/3 ML) SUBCUTANEOUS PEN  
INJECTOR..... 5

VIIBRYD 10 MG (7)-20 MG (23)  
TABLETS IN A DOSE PACK..... 2

VIIBRYD 10 MG TABLET ..... 2

VIIBRYD 20 MG TABLET ..... 2

VIIBRYD 40 MG TABLET ..... 2

VIMPAT 10 MG/ML ORAL SOLUTION. 1

VIMPAT 100 MG TABLET ..... 1

VIMPAT 150 MG TABLET ..... 1

VIMPAT 200 MG TABLET ..... 1

VIMPAT 50 MG TABLET ..... 1

**Z**

zafirlukast 10 mg tablet..... 14

zafirlukast 20 mg tablet..... 14

ZIRGAN 0.15 % EYE GEL..... 15